Open Collections

UBC Faculty Research and Publications

Omalizumab in patients with severe asthma and persistent sputum eosinophilia Mukherjee, Manali; Kjarsgaard, Melanie; Radford, Katherine; Huang, Chynna; Leigh, Richard; Dorscheid, Delbert R; Lemiere, Catherine; Boulet, Louis-Philippe; Waserman, Susan; Martin, James; et al.

Abstract

Omalizumab, a recombinant humanized monoclonal antibody targeting the IgE molecule, is the first biologic approved for moderate-to-severe allergic asthmatics, who remain uncontrolled despite high dose inhaled corticosteroid and bronchodilators. Steroid-sparing effect of omalizumab has not been demonstrated in asthmatics with persistent airway eosinophilia in a randomised controlled trial till date. From this double-blind, placebo-controlled, multi-centred, randomized parallel group design, we report that omalizumab is possibly inadequate to control sputum eosinophilia, and therefore may not have a steroid-sparing effect, especially in those maintained on oral corticosteroids daily. This needs to be confirmed or refuted in a larger trial, which may be a challenge with respect to recruitment, since there are currently three additional biologics available to prescribe. Trial registration Clinicaltrials.gov, NCT02049294, Registered 30th January 2014, https://clinicaltrials.gov/ct2/show/NCT02049294

Item Metadata

Title
Omalizumab in patients with severe asthma and persistent sputum eosinophilia
Creator
Mukherjee, Manali; Kjarsgaard, Melanie; Radford, Katherine; Huang, Chynna; Leigh, Richard; Dorscheid, Delbert R; Lemiere, Catherine; Boulet, Louis-Philippe; Waserman, Susan; Martin, James; Nair, Parameswaran
Publisher
BioMed Central
Date Issued
2019-04-03
Description
Omalizumab, a recombinant humanized monoclonal antibody targeting the IgE molecule, is the first biologic approved for moderate-to-severe allergic asthmatics, who remain uncontrolled despite high dose inhaled corticosteroid and bronchodilators. Steroid-sparing effect of omalizumab has not been demonstrated in asthmatics with persistent airway eosinophilia in a randomised controlled trial till date. From this double-blind, placebo-controlled, multi-centred, randomized parallel group design, we report that omalizumab is possibly inadequate to control sputum eosinophilia, and therefore may not have a steroid-sparing effect, especially in those maintained on oral corticosteroids daily. This needs to be confirmed or refuted in a larger trial, which may be a challenge with respect to recruitment, since there are currently three additional biologics available to prescribe. Trial registration Clinicaltrials.gov, NCT02049294, Registered 30th January 2014, https://clinicaltrials.gov/ct2/show/NCT02049294
Subject
Severe asthma; Sputum eosinophils; Omalizumab; IgE; TSLP
Genre
Article
Type
Text
Language
eng
Date Available
2019-04-03
Provider
Vancouver : University of British Columbia Library
Rights
Attribution 4.0 International (CC BY 4.0)
DOI
10.14288/1.0377777
URI
http://hdl.handle.net/2429/69429
Affiliation
Medicine, Faculty of; Non UBC; Medicine, Department of
Citation
Allergy, Asthma & Clinical Immunology. 2019 Apr 03;15(1):21
Publisher DOI
10.1186/s13223-019-0337-2
Peer Review Status
Reviewed
Scholarly Level
Faculty
Copyright Holder
The Author(s)
Rights URI
http://creativecommons.org/licenses/by/4.0/
Aggregated Source Repository
DSpace

Item Media

Item Citations and Data

Rights

Attribution 4.0 International (CC BY 4.0)